Evolución clínico funcional de pacientes con fibrosis quística tratados con lumacaftor/ivacaftor en un centro pediátrico. Serie de casos

Fernández Sardá, M. Sol; Báez Mellid, Lourdes; Brizuela, Paula; Dicembrino, Manuela; Giugno, Hilda; Castaños, Claudio.
Arch. argent. pediatr ; 121(5): e202202825, oct. 2023. tab, graf
Artigo em Inglês, Espanhol | LILACS, BINACIS | ID: biblio-1510083

Similares

  1. Clinical and functional course of patients with cystic fibrosis treated with lumacaftor/ivacaftor at a children's hospital. A case series.
  2. Cystic Fibrosis: A Review.
  3. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection.
  4. The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor.
  5. Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials.
  6. Antimicrobial susceptibility and genotyping of microorganisms isolated from sputum culture of children with cystic fibrosis in an Iranian referral children's hospital.
  7. Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis.
  8. PTENtiating CFTR for Antimicrobial Immunity.
  9. Special Issue Editorial: "Antibacterial Agents from Natural Sources".
  10. Heterogenous biofilm mass-transport model replicates periphery sequestration of antibiotics in <i>Pseudomonas aeruginosa</i> PAO1 microcolonies.